To study and compare the effect of vaginal sildenafil and estradiol valerate on endometrial thickness, blood flow and pregnancy rates in infertile women undergoing intrauterine insemination -
Abstract
Background: The objective of this study was to study and compare the effect of vaginal sildenafil citrate and estradiol valerate on endometrial thickness, blood flow and pregnancy rates in infertile women undergoing intrauterine insemination (IUI). Methods: It is a comparative prospective study including 100 women with primary or secondary infertility with stimulated cycles undergoing IUI. Patients with thin endometrium were randomly distributed in two groups. In group A, 50 patients were included and given sildenafil citrate 25 mg vaginally every 6 hours from day 8 th of the cycle. In group B, 50 patients were given tablet estradiol valerate 2 mg 6-8 hourly. Patients were evaluated by trans-vaginal sonography (TVS) on day 13 th of cycle for endometrial thickness and pattern with number and size of Graffian follicle. Results: Mean endometrial thickness at the time of hCG trigger was 9.42 mm in sildenafil group and 9.94 mm in estradiol group (p value 0.14). 64% patients given sildenafil vaginally had vascularity up to zone 3 whereas 48% patients given estradiol valerate orally had zone 3 endometrial vascularity (p value = 0.038). The clinical pregnancy rates were 10 (20%) in group 1 and 7 (14%) in group 2 after 3 cycles of IUI. (p value = 0.042). Conclusions: Both estradiol valerate and Sildenafil citrate can be used for improving the endometrium. Sildenafil when compared to estradiol valerate has better results as far as endometrial vascularity is concerned and marginally…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.